Center for Veterinary Medicine: Overview Sanja Modric, DVM, PhD
|
|
|
- Geraldine Barker
- 9 years ago
- Views:
Transcription
1 Center for Veterinary Medicine: Overview Sanja Modric, DVM, PhD Office of New Animal Drug Evaluation Center for Veterinary Medicine Food and Drug Administration USP Veterinary Stakeholder Forum,
2 FDA Center for Veterinary Medicine What we regulate: Animal drugs Animal feeds Veterinary devices What we do not regulate: The practice of veterinary medicine Vaccines for animals (USDA)
3 Core CVM Mission Protecting human and animal heath
4 Core CVM Mission Companion Animals Increase quality of life through medical interventions Ensure the availability of animal drugs that prevent the spread of zoonotic diseases 58 62% of households own a pet 44% of dogs sleep in the owners bed
5 Core CVM Mission Food Producing Animals Improve animal welfare and health Improve animal production Increase the availability of food supply to meet the needs of a growing human population
6 FDA CVM: Major Responsibilities Evaluation of data on proposed new veterinary products prior to approval Monitoring for violative marketed products through surveillance programs Ensuring animal feed safety Initiating legal action, if necessary, to bring violators into compliance with the law Conducting research to support Center activities Educating consumers and regulated industry USP Veterinary Stakeholder Forum, 11/09/2012
7 Laws Enforced by CVM Federal Food, Drug and Cosmetics (FFD&C) Act (1938) Animal Drug Amendments of 1968 Specific Animal Drug Acts: Animal Drug Availability Act of 1996 Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) Generic Animal Drug and Patent Term Restoration Act (GADPTRA) Minor Use/Minor Species Act of 2004 (MUMS) Animal Drug User Fee Act of 2008 (ADUFA) Animal Generic Drug User Fee Act of 2008 (AGDUFA)
8 Federal Food, Drug, and Cosmetic Act (1938) Chapter II FFD&C Act Chapter II, Sec. 321(g)(1) The term "drug" means: (A) articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; (C) articles (other than food) intended to affect the structure or any function of the body of man or other animals; (D) articles intended for use as a component of any article specified in clause (A), (B), or (C)
9 Federal Food, Drug, and Cosmetic Act (1938) Chapter V Sec. 501 A drug shall be deemed to be adulterated if it purports to be or is represented as a drug the name of which is recognized in an official compendium (USP-NF), and its strength differs from, or its quality or purity falls below, the standards set forth in such compendium. Such determination as to strength, quality, or purity shall be made in accordance with the tests or methods of assay set forth in such compendium Sec. 502 A drug shall be deemed to be misbranded - if it purports to be a drug the name of which is recognized in an official compendium, (USP-NF) unless it is packaged and labeled as prescribed therein
10 FDA - Approval and Regulations of Animal Drugs Similar in theory and practice to the approval of human drugs Multiple species considerations Approval only for specific uses/species with adequate safety and effectiveness data Companion-animal drugs - more similar to human approval process Food-animal drugs - human food safety requirements: Toxicology (Delaney clause FD&C amendment of 1938) Limits for drug residues set
11 Code of Federal Regulations (CFR) The codification of the general and permanent rules published in the Federal Register by the executive departments and agencies of the Federal Government Divided into 50 titles that represent broad areas subject to Federal regulation: CFR Title 21 - Food and Drugs: Parts 1 to 1499
12 Human vs. Animal Drugs: Comparison of CFR* What s the same? CDER Title CVM Title 300 General 500 Animal Drugs, Feeds, Related Products 310 New Drugs 510 New Animal Drugs 312 Investigational New Drug Application 314 Applications for FDA Approval 511 New Animal Drugs for Investigational Use 514 New Animal Drug Applications 316 Orphan Drugs 516 New Animal Drugs for MUMS Tables modified from Dr. Michael Murphy s presentation at the AAVPT Veterinary Drug Regulatory Life- Cycle Course (February 2011)
13 Human vs. Animal Food: Comparison of CFR What s similar? CFSAN Title CVM Title 101 Food Labeling 501 Animal Food Labeling 102 Common or Usual Name 109 Unavoidable contaminants in food 502 Common or Usual Name for Nonstandardized animal foods 509 Unavoidable contaminants in animal food 170 Food additives 570 Food Additives 171 Food additive petitions 571 Food Additive Petitions
14 CFR What s Unique for Vet. Drugs CVM Title 515 Medicated feed mill license 520 Oral dosage form new animal drugs 522 Implantation or injectable dosage form new animal drugs 524 Ophthalmic and topical dosage form new animal drugs 526 Intramammary dosage form 528 New animal drugs in genetically engineered animals 529 Certain other dosage form new animal drugs 530 Extralabel drug use in animals 556 Tolerances for residues of new animal drugs in food 558 New animal drugs for use in animal feeds
15 New Animal Drugs Code of Federal Regulation Title 21 Food and Drugs Chapter I Food and Drug Administration Subchapter E- Animal Drugs, Feeds, and Related Products Part 510 New Animal Drugs: The term new animal drug means any drug intended for use for animals other than man, including any drug intended for use in animal feed but not including such animal feed
16 Critical Standards for Evaluation of New Animal Drugs Safety Human Food Target Animal Environmental User Safety Effectiveness - Substantial Evidence Quality Manufactured Product Properly Labeled Product
17 FDA and USP FDA Protects public and animal health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biologial products, medical devices, food, cosmetics, dietary supplements USP Sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements No enforcement role; enforcement through FDA
18 FDA and USP FDA Protects public and animal health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products, medical devices, food, cosmetics, dietary supplements USP Sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements No enforcement role; enforcement through FDA
19 FDA (CVM) and USP CVM responsibilities: Review of bi-monthly U.S. Pharmacopeial Forum (USP-PF) issuances and frequent U.S. Pharmacopeia-National Formulary (USP-NF) revision proposals Input from pertinent office(s)/division(s) Collaboration with CDER (Compendial Operations) Feedback to USP on materials posted in PF or in the USP-NF as they relate to veterinary drugs
20 CVM and USP Collaborations Expert Committees: General Chapters Dosage Forms: Modric General Chapters Chemical Analysis: TBD Nomenclature, Safety and Labeling: Modric Monographs Small molecules 3: Modric Compounding: Bray, Modric
21 CVM and USP Collaborations Expert Panels: Metal Impurities: Guo Veterinary Drugs Solubility Criteria: Martinez and Modric
22 Thank you!
2014 Annual Report on Inspections of Establishments
2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered
The United States Pharmacopeia
INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29 February to 2 March 2012 The United States Pharmacopeia Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Roger L.
Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs
Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health
CDRH Regulated Software
CDRH Regulated Software An Introduction John F. Murray Jr. CDRH Software Compliance Expert CDRH Regulates Software in the following areas Medical Devices Automation of Production Systems Automation of
Veterinary Compounding
Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Minnesota Board of Pharmacy. Guidance on the Compounding of Veterinary Products Approved: March 4, 2015
EXECUTIVE SUMMARY Minnesota Board of Pharmacy Guidance on the Compounding of Veterinary Products Approved: March 4, 2015 Board staff has held several meetings with representatives of the Minnesota Veterinary
Guidance for Industry
Guidance for Industry FDA Export Certificates Submit comments and suggestions regarding this document at anytime to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Guidance for Industry Certification Process for Designated Medical Gases
Guidance for Industry Certification Process for Designated Medical Gases DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection
Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection U.S. Department of Health and Human Services Food and Drug Administration Office of Regulatory
FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle
FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle Kurt R. Karst Associate Hyman, Phelps & McNamara, P.C. 700 Thirteenth
Guidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.
Regulation and Risk Management of Combination Products
Regulation and Risk Management of Combination Products Katherine Ulman Associate Scientist Global Regulatory Compliance Manager Dow Corning Healthcare Jim Curtis Senior Specialist, Healthcare Applications
United States Pharmacopeia (USP) Quality Standards for Dietary Supplements. Nandu Sarma, PhD, RPh. Director, Dietary Supplements
United States Pharmacopeia (USP) Quality Standards for Dietary Supplements Nandu Sarma, PhD, RPh. Director, Dietary Supplements ACPM webinar, July 17, 2014 Objectives Describe the dietary supplement regulations
Guidance for Industry
Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
Commentary USP 36-NF 31. Excerpt Related to General Chapter <17> Prescription Container Labeling
Commentary USP 36-NF 31 Excerpt Related to General Chapter Prescription Container Labeling In accordance with USP s Rules and Procedures of the Council of Experts ( Rules ), USP publishes all proposed
(1) Cancer drug means a prescription drug that is used to treat cancer or the side effects of cancer.
DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT Health Promotion and Disease Prevention Services CANCER DRUG REPOSITORY PROGRAM 6 CCR 1015-10 [Editor s Notes follow the text of the rules at the end of this
Guidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
ENFORCEMENT PRIORITIES FOR DRUG USE IN AQUACULTURE PART A ENFORCEMENT PRIORITIES FOR DRUG USE IN NON-FOOD FISH
CENTER FOR VETERINARY MEDICINE PROGRAM POLICY AND PROCEDURES MANUAL 1240.4200 SUPPLEMENTAL POLICIES ENFORCEMENT PRIORITIES FOR DRUG USE IN AQUACULTURE PART A ENFORCEMENT PRIORITIES FOR DRUG USE IN NON-FOOD
[DOCKET NO.96N-0002] DRAFT
[DOCKET NO.96N-0002] DRAFT DRAFT DOCUMENT CONCERNING THE REGULATION OF PLACENTAL/UMBILICAL CORD BLOOD STEM CELL PRODUCTS INTENDED FOR TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECTABLE PRODUCTS DECEMBER,
IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013
Exempt Sections within the Food, Drug, and Cosmetic Act If a "traditional compounder", defined as a licensed pharmacist or licensed physician, meets ALL conditions within Section 503A, the compounder is
http:www.aphis.gov/animal_health/vet_accreditation/training_modules.shtml
APHIS Approved Supplemental Training for Accredited Veterinarians has now been approved for Continuing Education Credit by the Texas Board of Veterinary Medical Examiners In the new accreditation process,
Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,
Reprinted from FDA s website by Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Guidance And Antiasthmatic for Drug Industry Products for Over-the-Counter Labeling
Plamena Entcheva-Dimitrov, PhD, RAC On-line Course. www.preferredregulatoryconsulting.com 1
Plamena Entcheva-Dimitrov, PhD, RAC On-line Course 1 The Preferred Regulatory Consulting content in this presentation is copyright protected under United States law and applicable international copyright
Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
An Overview of the Regulation of Homeopathic Drug Products in the United States
An Overview of the Regulation of Homeopathic Drug Products in the United States and the Role of the Homoeopathic Pharmacopoeia Convention of the United States J.P. Borneman, Ph.D. President, Homoeopathic
Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair. February 19, 2014
Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair February 19, 2014 FDA Mission FDA is responsible for: Protecting the public health by assuring that foods are safe,
Drug Development Process
Drug Development Process Original Arthur: Addie D. Anderson CRB Consulting Engineers, Inc. Overview Important milestones establishing our current system of regulations Step-by-step overview of the drug
Pre-Approval Process INAD vs. NADA
Pre-Approval Process INAD vs. NADA Barbara M. Leotta, DVM CVM/ONADE/DTDNFA (240)276-8262 [email protected] Pre-Approval Process General Overview Pathways To Legal Marketing Office of New Animal
FDA Regulation of Hearing Aids. Eric A. Mann, MD, PhD Clinical Deputy Director Division of Ophthalmic and ENT Devices ODE/CDRH/FDA
FDA Regulation of Hearing Aids Eric A. Mann, MD, PhD Clinical Deputy Director Division of Ophthalmic ENT ODE/CDRH/FDA U.S. Food Drug Administration Presentation Outline Overview of device regulations riskbased
Guidance for Industry
Guidance for Industry Submitting Debarment Certification Statements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
1083.4 SUPPLY CHAIN INTEGRITY AND SECURITY
BRIEFING 1083.4 Supply Chain Integrity and Security. A new series of general informational chapters describing various aspects of the pharmaceutical supply chain replaces Good Distribution Practices Supply
Inspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.
GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.
GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au
Catalog. Global Education. and Training. Global Expertise Trusted Standards Improved Health
Global Education Catalog 2013 2014 and Training Global Expertise Trusted Standards Improved Health USP s mission is to improve global health through public standards and related programs that help ensure
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Drug Establishment Registration and Drug Listing U.S. Department of Health and Human Services Food and Drug Administration Office
Guidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
Medical Device Software
Medical Device Software Bakul Patel Senior Policy Advisor 1 Overview Medical devices and software Oversight principles and Current approach Trends, Challenges and opportunities Addressing challenges 2
What is a medical device? Medical Devices: Roadmap to Market. Kathryn Klaus, Esq.
Medical Devices: Roadmap to Market Kathryn Klaus, Esq. The last installment of Regulatory 360 discussed the FDA organization in general where it came from and a broad overview of how it operates, as well
Combination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation
Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Leslie M. Tector Quarles & Brady LLP September 30, 2014 Objectives Which federal
General Wellness: Policy for Low Risk Devices. Draft Guidance for Industry and Food and Drug Administration Staff
General Wellness: Policy for Low Risk Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document
Correspondence between ISO 13485:2003 and the US Quality System Regulation
Correspondence between ISO 13485:2003 and the US Quality System Regulation Correspondence between ISO 13485:2003 and the US Quality System Regulation 1 Scope 1.1 General This International Standard specifies
Guidance for Industry
Guidance for Industry Changes to an Approved NDA or ANDA U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) April 2004 CMC Revision
POLICY AND PROCEDURES OFFICE OF NEW DRUGS. NDAs and BLAs: Communication to Applicants of Planned Review Timelines.
CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 6010.8 Rev. 1 POLICY AND PROCEDURES OFFICE OF NEW DRUGS NDAs and BLAs: Communication to Applicants of Planned Review Timelines Table of Contents PURPOSE...1
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
Guidance for Industry
Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts
RSPT 2217 & Principles Gardenhire Chapter 1; p. 1-10 From the Text Key Terms and page 2 Orphan Drugs Table 1-1; page 6 Abbreviations Table 1-2; page 8 Aerosolized Agents Table 1-3; page 9 Drug: Pharmacology:
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Guidance for Industry
Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Adjuvants and Excipients
Adjuvants and Excipients The Food Safety and Inspection Service (FSIS) transferred the official responsibility to evaluate adjuvants and excipients used in Veterinary Biologics back to the Animal and Plant
Pharmacists Pharmacopeia. Official May 1, 2009 August 1, 2009
3 Pharmacists Pharmacopeia Official May 1, 2009 August 1, 2009 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Pharmacists Pharmacopeia of a monograph on any drug
Development and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO
Development and Validation of In Vitro Diagnostic Tests YC Lee, Ph.D. CEO 1 Validation of In Vitro Diagnostic Tests Validated d Diagnostic Test should: Provides test results that identify if positive i
FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL
FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM 7356.002F CHAPTER 56 DRUG QUALITY ASSURANCE SUBJECT: ACTIVE PHARMACEUTICAL INGREDIENT (API) PROCESS INSPECTION Revision Note: Program
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health
Safe%Feed/Safe%Food% Overview of Certification Programs: Why Should a Feed Mill Get Certified?
Safe%Feed/Safe%Food% Overview of Certification Programs: Why Should a Feed Mill Get Certified? Henry Turlington, Ph.D. Director, Quality & Manufacturing Regulatory Affairs American Feed Industry Association
Best Practices for Use of FoodSHIELD During Food and Feed Incidents
Partnership for Food Protection s Surveillance, Response and Post Response Workgroup presents Best Practices for Use of FoodSHIELD During Food and Feed Incidents Summer 2015 1 Table of Contents: Cover
AMBERLITE IRP69 Pharmaceutical Grade Cation Exchange Resin (Sodium Polystyrene Sulfonate USP)
AMBERLITE IRP69 Pharmaceutical Grade Cation Exchange Resin (Sodium Polystyrene Sulfonate USP) Description AMBERLITE IRP69 [1] resin is an insoluble, strongly acidic, sodium form cation exchange resin supplied
Medical Product Software Development and FDA Regulations Software Development Practices and FDA Compliance
Medical Product Development and FDA Regulations IEEE Orange County Computer Society March 27, 2006 Carl R. Wyrwa Medical Product Development and FDA Regulations Introduction Regulated FDA Overview Medical
Implementing New USP Chapters for Analytical Method Validation
Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: [email protected] Today s Agenda Handling Method Changes vs. Adjustments
Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers
Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
Department of Defense DIRECTIVE
Department of Defense DIRECTIVE NUMBER 6400.04E June 27, 2013 Incorporating Change 1, Effective October 18, 2013 USD(P&R) SUBJECT: DoD Veterinary Public and Animal Health Services References: See Enclosure
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
General Principles for the Safety Assessment of Excipients
General Principles for the Safety Assessment of Excipients General Characteristics of the Pharmaceutical Excipients Classification of excipients The Safety Assessment of Pharmaceutical Excipients : how
Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories
14 1 2 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 21 22 23 24 25 26 27 Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories Framework for Regulatory Oversight of
Guidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
MOBILE MEDICAL APPLICATIONS
October 7, 2013 EVOKE HEALTH POINT OF VIEW MOBILE MEDICAL APPLICATIONS FDA GUIDANCE FOR INDUSTRY FOR MORE INFORMATION: Mark McConaghy, VP, Strategy Evoke Health 267.765.4998 [email protected]
USP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants
USP Pharmaceutical Ingredient Supplier Qualification Program Manual for Participants UNITED STATES PHARMACOPEIA Drug Substance Supplier Qualification Program ICE This manual provides information to drug
The Sheep Safety and Quality Assurance Program. Melissa Garrod-VanLaningham, DVM
The Sheep Safety and Quality Assurance Program Melissa Garrod-VanLaningham, DVM THE MISSION OF SSQA Maximize consumer confidence in, and acceptance of, sheep products by using research and education to
Chapter No. 765] PUBLIC ACTS, 2004 1 CHAPTER NO. 765 HOUSE BILL NO. 3229. By Representatives West, Marrero. Substituted for: Senate Bill No.
Chapter No. 765] PUBLIC ACTS, 2004 1 CHAPTER NO. 765 HOUSE BILL NO. 3229 By Representatives West, Marrero Substituted for: Senate Bill No. 2840 By Senator Cohen AN ACT to amend Tennessee Code Annotated,
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
Annex 9 Guide to good storage practices for pharmaceuticals 1
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities
2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC
2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC Objectives 1. Review the changes to the pharmacy practice act related to sterile compounding. 2. Understand the role of the
CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair. March 3, 2015
Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair March 3, 2015 Agenda Who we are What we buy Goals and statistics Partnering with OAGS 2 FDA Mission FDA is responsible
Enrolled Copy H.B. 128
1 ELECTRONIC PRESCRIBING ACT 2 2009 GENERAL SESSION 3 STATE OF UTAH 4 Chief Sponsor: Ronda Rudd Menlove 5 Senate Sponsor: Peter C. Knudson 6 Cosponsor: Evan J. Vickers 7 8 LONG TITLE 9 General Description:
Re: GRAS Notice No. AGRN 000-009
May 4, 2012 Dr. Hardy Edwards III Vitamin Derivatives, Inc. 625 Lem Edwards Road Winterville, Georgia 30683 Re: GRAS Notice No. AGRN 000-009 Dear Dr. Edwards: The Food and Drug Administration (FDA) is
Have you ever wanted to help animals and people stay healthy? Have you ever thought about working in veterinary medicine? Well, I m here to explain
Have you ever wanted to help animals and people stay healthy? Have you ever thought about working in veterinary medicine? Well, I m here to explain what veterinarians do and answer some of your questions.
Food and Drug Administration
Center for Drug Evaluation and Research (CDER) Small Business Assistance Program The Information Source for Regulated Domestic and International Small Pharmaceutical Business CAPT Brenda Stodart, USPHS
USP s mission is to improve global health through public. standards and related programs that help ensure the quality,
2015 Catalog USP s mission is to improve global health through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods. 2 Courses listed as of January
SUMMARY REPORT. Antimicrobials Sold or Distributed for Use in Food-Producing Animals
2009 SUMMARY REPORT On Antimicrobials Sold or Distributed for Use in Food-Producing Animals Food and Drug Administration Department of Health and Human Services September, 20 This version supersedes the
Food and Drug Administration COMMISSIONER S. Fellowship Program. Protecting Public Health Through Science and Regulation
DEPARTMENT OF HEALTH & HUMAN SERVICES USA Food and Drug Administration COMMISSIONER S Fellowship Program Protecting Public Health Through Science and Regulation FDA MISSION The FDA is responsible for protecting
Blood, Plasma, and Cellular Blood Components INTRODUCTION
Blood, Plasma, and Cellular Blood Components INTRODUCTION This chapter of the Guideline provides recommendations to Sponsors of Requests for Revision for new monographs for blood, plasma, and cellular
PRINCIPLES OF VETERINARY MEDICAL ETHICS OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (AVMA)
PRINCIPLES OF VETERINARY MEDICAL ETHICS OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (AVMA) (Bold print states the Principles, standard print explains or clarifies the Principle to which it applies)
